Cannabis use and abuse correlates in a homogeneous South African schizophrenia population

South African Journal of Psychiatry

Volumn 15, Issue 1, 2009, Pages 8-12

  Koen, L ^a   Jonathan, R ^a   Niehaus, D J H ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ADULT; AGED; ALCOHOL ABUSE; APATHY; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DELUSION; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG SCREENING; FEMALE; FUNCTIONAL ASSESSMENT; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; ONSET AGE; PREVALENCE; RELAPSE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SCORING SYSTEM; SEX DIFFERENCE; SMOKING; SOUTH AFRICA; SYMPTOMATOLOGY; URINALYSIS;

EID: 66749112402     PISSN: 16089685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Department of Health and Human Services: Substance Abuse and Mental Health Services Administration Office. Results from the 2006 National Survey on Drug Use and Health: National Findings. Rockville, MD, USA: SAMHSA, Office of Applied Studies, 2007.
2. United Nations Office on Drugs and Crime. 2008 World Drug Report. Vienna: United Nations, 2008.
3. Faris C, Brems C, Johnson M, Wells R, Burns R, Kletti N. A comparison of schizophrenic patients with or without coexisting substance use disorder. Psychiatric Quarterly 2003; 74: 205-222.
4. Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller A, Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997; 23: 195-201.
5. Bartels S, Teague G, Drake R, Clark R, Bush P, Noordsy D. Service utilization and costs associated with substance use among rural schizophrenic patients. J Nerv Ment Dis 1993; 181: 227-232.
6. Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005; 187: 306-313.
7. Salyers M, Mueser K. Social functioning, psychopathology and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res 2001; 48: 109-123.
8. Swartz M, Wagner H, Swanson J, et al. Substance use in persons with Schizophrenia: Baseline prevalence and correlates from the NIMH CATIE Study. J Nerv Ment Dis 2006; 194: 164-172.
9. Mueser K, Drake R, Ackerson T, Alterman A, Miles K, Noordsy D. Antisocial personality disorder, conduct disorder, and substance abuse in schizophrenia. J Abnorm Psychol 1997; 106: 473-477.
10. Caspari D. Cannabis and schizophrenia: results of a follow up study. Eur Arch Psychiatry Clin Neurosci 1999; 249: 45-49.
11. Buhler B, Hambrecht M, Loffler W, Van der Heiden W, Hafner H. Precipitation and determination of the course and onset of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002; 54: 243-251.
12. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-1486.
13. Van Os J, Bak M, Hanssen M, Bijl R, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156: 319-327.
14. Arseneault L, Cannon M, Witton J, Murray R. Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry 2004; 184: 110-117.
15. Peltzer K, Ramlagan S. Cannabis use trends in South Africa. South African Journal of Psychiatry 2007; 13(4): 126-131.
16. Koen L, Uys S, Niehaus D, Emsley R. Negative symptoms and HIV/AIDS risk behavior in schizophrenia. Psychosomatics 2007; 48: 128-134.
17. Koen L, Kinnear C, Corfield V, et al. Violence in male patients with schizophrenia: risk markers in a South African population. Aust N Z J Psychiatry 2004; 38: 254-259.
18. Nurnberger J, Blehar M, Kaufmann C, et al. Diagnostic interview for genetic studies. Rationale, unique features and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994; 51: 849-859.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD, USA: National Institute of Mental Health, 1976: 534-537.
20. Kavanagh D, Waghorn G, Jenner L, et al. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophr Res 2004; 66: 115-124.
21. Veen N, Selton J, Van der Tweel, I, Fella W, Hoek H, Kahn R. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004; 161: 501-506.
22. Linszen D, Dingemans P, Lenior M. Cannabis abuse and the course of recent onset schizophrenia disorders. Arch Gen Psychiatry 1994; 51: 273-279.
23. Caspi A, Moffitt T, Cannon M, et al. Moderation of the affect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57: 1117-1127.
24. South African Community Epidemiology Network on Drug Use. Alcohol and Drug Abuse Trends: Updates Jan 2002 - December 2006. Cape Town: Medical Research Council, November 2002 - May 2007.
25. Niehaus D, Koen L, Laurent C, et al. Positive and negative symptoms in affected sib pairs with schizophrenia: Implications for genetic studies in an African Xhosa sample. Schizophr Res 2005; 79: 239-249.
26. Stein D, Seedat S, Herman A, et al. Lifetime prevalence of psychiatric disorders in South Africa. Br J Psychiatry 2008; 192: 112-117.
27. Gastrow P. Mind-blowing: The Cannabis Trade in Southern Africa. Cape Town: Institute for Security Studies, 2003.
28. Niehaus DJH, Du Plessis S, Koen L, et al. Predictors of abnormal involuntary movement in an African schizophrenia population. J Neuropsychiatry Clin Neurosci 2008; 20(3): 317-326.
29. Muller-Vahl K. Cannabinoids reduce symptoms of Tourette's syndrome. Expert Opin Pharmacother 2003; 4: 1717-1725.